Luciferase Reporter Cell Line - HL-1

HL-1 cells constitute a mature murine cardiomyocyte cell line, originally isolated from an atrial cardiomyocyte tumor. This cell line is highly regarded for retaining many of the differentiated characteristics of adult cardiomyocytes. These features include cardiac-specific gene expression, spontaneous contractile activity under appropriate culture conditions, and responsiveness to physiological and pharmacological stimuli relevant to cardiac biology. The HL-1 Luciferase Reporter Cell Line is an engineered derivative of the parental HL-1 cell line, modified to stably express a luciferase reporter gene. Through stable genomic integration and selection, this cell line delivers a highly consistent luciferase signal output across multiple passages, enabling researchers to utilize sensitive bioluminescent readouts for the real-time monitoring of cell number, viability, proliferation, survival status, or experimental changes associated with specific signaling pathways.

The HL-1 Luciferase Reporter Cell Line finds broad application across various research disciplines, including cardiovascular biology, pharmacology, toxicology, and molecular biology. In the context of drug discovery and compound screening, this cell line serves as a quantitative surrogate marker; by detecting changes in luciferase activity, researchers can assess the impact of candidate drug molecules on cardiomyocyte viability, growth status, cytotoxicity, or stress responses. Furthermore, this cell line is particularly well-suited for cardiotoxicity assessment studies. In such studies, researchers often require a detection system that is both sensitive and scalable to compare the specific effects of small-molecule drugs, biologics, environmental chemicals, or pharmaceutical excipients on cardiomyocyte-like cells. Within the field of cardiovascular disease research, HL-1-Luc cells provide robust support for experimental models investigating oxidative stress, hypoxia/reoxygenation injury, inflammatory stimuli, metabolic disorders, and other mechanisms related to myocardial injury or cardioprotection.